Bl-logo high res_260x130px.jpg

BOEHRINGER INGELHEIM

line (1).png
BI Photo 1 - Glyxambi Logo_600x450px
BI Photo 1 - Glyxambi Logo_600x450px

BI Photo 2 - Jardiance Logo_600x450px
BI Photo 2 - Jardiance Logo_600x450px

BI Photo 3 - Trajenta Logo_600x450px
BI Photo 3 - Trajenta Logo_600x450px

BI Photo 1 - Glyxambi Logo_600x450px
BI Photo 1 - Glyxambi Logo_600x450px

1/3

COMPANY INFORMATION

line (1).png

Improving the health and quality of life of patients is the goal of the research-driven pharmaceutical company Boehringer Ingelheim. The focus in doing so is on diseases for which no satisfactory treatment option exists to date. The company therefore concentrates on developing innovative therapies that can extend patients’ lives. In animal health, Boehringer Ingelheim stands for advanced prevention. 

Family-owned since it was established in 1885, Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies. Some 50,000 employees create value through innovation daily for the three business areas human pharmaceuticals, animal health and biopharmaceuticals. In 2018, Boehringer Ingelheim achieved net sales of nearly 17.5 billion euros. R&D expenditure, exceeding three billion euros, corresponded to 18.1 per cent of net sales. 

As a family-owned company, Boehringer Ingelheim plans in generations and focuses on long-term success. The company therefore aims at organic growth from its own resources with simultaneous openness to partnerships and strategic alliances in research. In everything it does, Boehringer Ingelheim naturally adopts responsibility towards mankind and the environment. 

More information about Boehringer Ingelheim can be found on www.boehringer-ingelheim.com.hk.

CONTACT INFORMATION

line (1).png

Contact:

Boehringer Ingelheim (Hong Kong) Limited

Telephone: +852 2596 0033

Email:

Website:

RESOURCES

line (1).png
BI Res2-s
BI Res3-s